Table 4.
Percentage of US Adults, Overall and in Selected Subgroups, Recommended Antihypertensive Medication According to the ACC/AHA Guideline, 2014 Expert Panel Report, and JNC7 Based on the 2013 to 2016 PINNACLE Registry Data
| Subgroups | ACC/AHA guideline | 2014 Report | Difference between ACC/AHA guideline and 2014 report | JNC7 | Difference between ACC/AHA guideline and JNC7 |
|---|---|---|---|---|---|
| Overall (N=6 042 630) | 70.60 (70.56–70.64) | 61.80 (61.76–61.84) | 8.80 (8.78–8.83) | 65.93 (65.89–65.96) | 4.67 (4.66–4.69) |
| Age group, y | |||||
| 18–44 (N=892 971) | 33.16 (33.06–33.26) | 30.14 (30.05–30.24) | 3.02 (2.99–3.06) | 31.56 (31.47–31.66) | 1.60 (1.57–1.62) |
| 45–54 (N=806 202) | 60.68 (60.58–60.79) | 55.20 (55.09–55.31) | 5.48 (5.43–5.53) | 57.75 (57.64–57.86) | 2.93 (2.90–2.97) |
| 55–64 (N=1 280 248) | 71.61 (71.53–71.69) | 64.20 (64.12–64.28) | 7.41 (7.36–7.45) | 68.40 (68.32–68.48) | 3.20 (3.17–3.23) |
| 65–74 (N=1 569 242) | 82.51 (82.45–82.57) | 69.68 (69.61–69.75) | 12.83 (12.78–12.88) | 75.30 (75.23–75.36) | 7.21 (7.17–7.25) |
| ≥75 (N=1 493 967) | 84.96 (84.90–85.01) | 73.94 (73.87–74.01) | 11.02 (10.97–11.07) | 78.91 (78.84–78.97) | 6.05 (6.01–6.09) |
| Men (N=2 888 411) | 75.05 (75.00–75.10) | 65.84 (65.78–65.89) | 9.21 (9.17–9.24) | 70.04 (69.99–70.09) | 5.01 (4.98–5.03) |
| Women (N=3 148 983) | 66.51 (66.46–66.56) | 58.08 (58.02–58.13) | 8.43 (8.40–8.46) | 62.14 (62.09–62.20) | 4.37 (4.34–4.39) |
| Race and ethnicity | |||||
| White (N=3 933 307) | 69.52 (69.48–69.57) | 60.18 (60.13–60.23) | 9.35 (9.32–9.37) | 64.56 (64.51–64.60) | 4.97 (4.94–4.99) |
| Black (N=432 202) | 74.40 (74.27–74.53) | 66.64 (66.50–66.78) | 7.76% (7.68–7.84) | 71.17 (71.04–71.31) | 3.23 (3.18–3.28) |
| Other * (N=28 139) | 70.44 (69.90–70.97) | 63.61 (63.04–64.17) | 6.83 (6.54–7.14) | 67.22 (66.66–67.76) | 3.22 (3.02–3.44) |
| Hispanic (N=255 374) | 68.35 (68.17–68.53) | 61.67 (61.48–61.85) | 6.69 (6.59–6.78) | 65.23 (65.05–65.42) | 3.12 (3.05–3.19) |
| Non‐Hispanic (N=5 787 256) | 70.70 (70.66–70.74) | 61.80 (61.76–61.84) | 8.90 (8.87–8.92) | 65.96 (65.92–65.99) | 4.74 (4.73–4.76) |
| 10‐y ASCVD risk categories, % | |||||
| <5 (N=30 796) | 45.82 (45.26–46.38) | 42.84 (42.29–43.40) | 2.97 (2.79–3.17) | 44.79 (44.23–45.35) | 1.03 (0.92–1.15) |
| 5–<10 (N=21 241) | 67.42 (66.78–68.05) | 59.97 (59.31–60.63) | 7.44 (7.09–7.80) | 64.20 (63.55–64.85) | 3.22 (2.98–3.46) |
| 10–<20 (N=24 609) | 85.56 (85.12–86.00) | 68.71 (68.13–69.29) | 16.85 (16.38–17.32) | 74.90 (74.35–75.44) | 10.67 (10.28–11.06) |
| ≥20 (N=21 394) | 92.59 (92.23–92.93) | 82.14 (81.62–82.65) | 10.45 (10.04–10.86) | 88.04 (87.60–88.48) | 4.54 (4.27–4.83) |
| History of CVD (N=2 585 483) | 85.82 (85.78–85.87) | 75.72 (75.67–75.77) | 10.10 (10.07–10.14) | 79.33 (79.28–79.38) | 6.49 (6.46–6.52) |
Proportions and 95% Clopper‐Pearson (exact) CIs were reported. ACC indicates American College of Cardiology; AHA, American Heart Association; ASCVD, atherosclerotic CVD; CVD, cardiovascular disease; JNC7, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; and PINNACLE, Practice Innovation and Clinical Excellence.
*Defined as combination of any race other than White or Black, including Asian, American Indian/Alaskan Native, Native Hawaiin/ Pacific Islander.